Drug Availability
HPS Pharmacies wish to give notice that there is a supply interruption for nifedipine as follows:
| Product |
ARTG |
Expected Return Date |
| Adefin® 10mg |
92999 |
Discontinued |
| Adalat® Oros 20mg |
60101 |
End June 2021 |
| Adalat® Oros 30mg |
76041 |
Early March 2021 |
| Addos® XR 30mg |
114825 |
Mid-late June 2020 |
| APO-Nifedipine XR 30mg |
152207 |
Mid-March 2020 |
| Adefin® XL 30mg |
91779 |
Discontinued |
| Adalat® Oros 60mg |
76040 |
End-May 2021 |
| Addos® XR 60mg |
98806 |
Mid-late June 2020 |
| Adefin® XL 60mg |
91779 |
Discontinued |
| APO-Nifedipine XR 60mg |
152208 |
Mid-March 2020 |
Limited supplies of nifedipine 30mg modified-release tablets are currently available at some warehouses. An internationally registered brand of nifedipine 30mg modified-release tablets and nifedipine 60mg modified-release tablets has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Other presentations of nifedipine may be accessed via the Special Access Scheme (SAS) if necessary. Please note that SAS and Section 19A alternatives are subject to a longer lead-time and different pricing as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Drug Availability
HPS Pharmacies wish to give notice that Alphapharm is experiencing a supply interruption for hydrocortisone tablets as follows:
Hysone® 20
Hydrocortisone 20mg
ARTG 27926
Hydrocortisone Mylan 4
Hydrocortisone 4mg
ARTG 290097
Normal supplies of Hysone® 20 are expected to resume in mid-March 2020. Hydrocortisone Mylan 4 is currently still available, although a supply interruption is anticipated through April 2020.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Alphapharm on 1800 274 276 or your pharmacist at HPS Pharmacies.
Drug Availability
HPS Pharmacies wish to give notice that Sanofi-Aventis is experiencing a supply interruption for Tilade® as follows:
Tilade® Metered Dose Aerosol
Nedocromil Sodium 2mg/actuation
ARTG 70238
Warehouses in some states may still have limited stock available. Normal supplies are expected to resume in early April 2020.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Sanofi-Aventis on 1800 818 806 or your pharmacist at HPS Pharmacies.
Drug Availability Update
Further to DrugAlert Vol 530, HPS Pharmacies wish to give notice that Aspen Pharmacare Australia Pty Ltd is continuing to experience a supply interruption for the following local anaesthetic products:
| Product |
ARTG |
Expected Return Date |
| Xylocaine® 2% with adrenaline 1:80,000 10 x 5mL |
54520 |
Early March 2020 |
| Marcain® 0.125% with Fentanyl 100mcg 5 x 20ml (sterile theatre pack) |
123384 |
Early May 2020 |
| Marcain® 0.5% Spinal Heavy 5 x 4mL (sterile theatre pack) |
125878 |
Early June 2020* |
| Marcain® 0.5% Spinal 5 x 4mL (sterile theatre pack) |
21016 |
Mid-April 2020 |
| Naropin® 0.2% 5 x 100mL Polybag (sterile theatre pack) |
12013 |
End April 2020* |
| Xylocaine® Pump Spray Nozzle 210mm x 10 (sterile theatre pack) |
48364 |
End April 2020 |
*Wholesalers in some states currently have limited stock
All other local anaesthetic products marketed by Aspen are currently available.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies, or Aspen Pharmacare Australia on 1300 659 646.
Drug Availability
HPS Pharmacies wish to give notice that Pfizer is experiencing a supply interruption for Glucose Intravenous Infusion as follows:
Glucose Intravenous Infusion BP 5% Vials
Glucose (as monohydrate) 5g/100mL
ARTG 11371
Normal supplies of glucose 5% in 100mL vials are expected to resume by 29th June 2020. Alternative options that may be considered during this supply interruption include glucose 5% in 250mL, 500mL, and 1000mL presentations.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Pfizer on 1800 675 229 or your pharmacist at HPS Pharmacies.
Drug Availability
HPS Pharmacies wish to give notice that Southern Cross Pharma is experiencing a supply interruption for ephedrine hydrochloride as follows:
Ephedrine Hydrochloride SXP Injection
Ephedrine Hydrochloride 30mg/1mL
ARTG 259672
Normal supplies are expected to resume in mid-March 2020. Warehouses in some states may still have limited stock available.
The following options may be considered, where clinically appropriate:
- Ephedrine Hydrochloride Aguettant 30mg/10mL pre-filled syringes;
- Ephedrine Wockhardt 30mg/10 mL ampoules;
- Ephedrine Hydrochloride MYX 25mg/1mL ampoules; and
- DBL Ephedrine Sulfate 30mg/1mL ampoules.
Please note that the ephedrine content is different for the above products.
Dose equivalencies:
- 30mg of ephedrine hydrochloride = 24.6mg of ephedrine
- 25mg of ephedrine hydrochloride = 20.5mg of ephedrine
- 30mg of ephedrine sulfate = 23.1mg of ephedrine
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Drug Availability
HPS Pharmacies wish to give notice that Key Pharmaceuticals is experiencing a supply interruption for OsmoLax® as follows:
| Product |
Pack Size |
Expected Return Date |
| OsmoLax® |
510g |
Late March 2020 |
| OsmoLax® Relief |
595g |
Late March 2020 |
| OsmoLax® Relief |
7 x 17g |
Early April 2020* |
| OsmoLax® Relief Child |
298g |
Early April 2020 |
*Warehouses may still have limited stock in some states
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies
Drug Availability Update
HPS Pharmacies wish to advise that there is currently a supply interruption for famotidine tablets as follows:
Ausfam 20
Famotidine 20mg
ARTG 93788
Ausfam 40
Famotidine 40mg
ARTG 93789
Supplies of Ausfam 20mg are expected to return to normal in late March 2020. Supplies of Ausfam 40mg are expected to return to normal in late February 2020. Supplies of APO-Famotidine are long-term out of stock.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Arrow Pharma on 1300 927 769 or your pharmacist at HPS Pharmacies.
Drug Availability Update
Further to DrugAlert Volume 485, HPS Pharmacies wish to give notice that Seqirus is continuing to experience a supply interruption for BenPen™ as follows:
BenPen™ Vials
Benzylpenicillin (as sodium) 600mg
ARTG 10329
BenPen™ Vials
Benzylpenicillin (as sodium) 1.2g
ARTG 10326
Normal supplies of BenPen™ 600mg and BenPen™ 1.2g are expected to resume by end of February 2020. An internationally registered brand of benzylpenicillin 600mg and 1.2g vials has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Please note that Section 19A alternatives are subject to a longer lead-time and different pricing as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Seqirus on (03) 9389 2000, or your pharmacist at HPS Pharmacies.
Drug Availability
HPS Pharmacies wish to give notice that Amdipharm Mercury Australia is experiencing a supply interruption for carbimazole as follows:
Neo-Mercazole® Tablets
Carbimazole 5mg
ARTG 194296
Availability is currently limited with normal supplies expected to resume by end of February 2020.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Amdipharm Mercury Australia on (02) 9431 6333 or your pharmacist at HPS Pharmacies.
